drugset
drugset / Trial / NCT00565487

Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic Cancer

NCT00565487 ↗

Phase 1 Completed 15 enrolled Milton S. Hershey Medical Center Genentech, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to determine the best dosage of Capecitabine and Tarceva combination in the setting of radiation and to assess treatment effectiveness, progression-free survival and overall survival.

Timeline

Start
2007-12
Primary completion
2014-08-05
Completion
2014-08-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 600 mg/m2 Oral
Subject Capecitabine Small molecule 700 mg/m2 Oral
Subject Capecitabine Small molecule 825 mg/m2 Oral
Subject Capecitabine Small molecule 925 mg/m2 Oral
Background Erlotinib Small molecule 100 mg Oral

Indications

malignant pancreatic neoplasm